Botulinum Toxin Type A injections for pediatric spasticity: Keeping our patients informed and practices safe
Serious adverse events (serious AEs) following the therapeutic use of Botulinum Toxin Type A (BoNT-A) are infrequent. Children with pediatric spasticity often have comorbidities that can cloud causation around an adverse event (AE). If a serious AE occurs, clear documentation of information sharing...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
SAGE Publishing
2021-06-01
|
| Серія: | Journal of Pediatric Rehabilitation Medicine |
| Онлайн доступ: | https://doi.org/10.3233/PRM-210031 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|